债券研究 证 券 研 究 报 告 【债券周报】 存单周报（1117-1123）：月末关注银行负债 边际变化 债券周报 2025 年 11 月 23 日 华创证券研究所 证券分析师：周冠南 电话：010-66500886 邮箱：zhouguannan@hcyjs.com 执业编号：S0360517090002 证券分析师：宋琦 电话：010-63214665 邮箱：songqi@hcyjs.com 执业编号：S0360523080002 相关研究报告 《【华创固收】政策双周报（0530-0612）：买断 式逆回购前置操作，中美经贸磋商原则上达成框 架 》 2025-06-12 《【华创固收】评级披露仍较缓慢，关注权益轮 动向转债传导——可转债周报 20250609》 2025-06-09 《【华创固收】央行开始买债了吗？——债券周 报 20250608》 2025-06-08 《【华创固收】存单周报（0602-0608）：资金预 期有所缓和，关注存单配置价值》 2025-06-08 《【华创固收】关注震荡市场利差被动走阔的加 仓机会——信用周报 20250607》 2025-06-07 证监会审核华创证券投资咨 ...

Investment Rating - The report maintains a "Buy" rating for the automotive sector, anticipating a bottoming and upward trend in Q1 2026 [1]. Core Insights - The automotive sector is currently experiencing a cooling sentiment due to the impact of trade-in quotas, with October retail sales falling below expectations and November expected to perform moderately. The fourth quarter is also anticipated to underperform previous market expectations. However, the sector is expected to find a bottom and begin to rise in Q1 2026, presenting potential investment opportunities for the upcoming year [1][2]. Data Tracking - In early November, the discount rate for vehicles increased to 10.0%, up by 0.4 percentage points month-on-month and 1.5 percentage points year-on-year. The average discount amount rose by 23,103 yuan, with significant fluctuations among major brands [3]. - In October, new energy vehicle deliveries from leading companies showed a notable increase for BYD, which delivered 442,000 units, a month-on-month increase of 11.5% but a year-on-year decrease of 12.1%. Other companies like Leap Motor and Xpeng also reported significant year-on-year growth [3][20]. - Traditional automakers also saw growth in October, with Geely's sales reaching 307,000 units, a year-on-year increase of 35.0% and a month-on-month increase of 12.5% [3][23]. Industry News - The report highlights several key developments in the automotive industry, including the launch of new models and significant sales figures for new energy vehicles. For instance, from November 1 to 16, the retail sales of new energy vehicles reached 554,000 units, a year-on-year increase of 2% [30][31]. - The report also notes the introduction of advanced technologies in new models, such as the Deep Blue L06 and the Xiaopeng X9, which feature cutting-edge battery systems and autonomous driving capabilities [30][31].

证 券 研 究 报 告 华创农业 10 月白羽肉禽月报 毛鸡价格稳后上扬，鸡苗价格高位偏强 ❑ 毛鸡&鸡苗：毛鸡价格稳后上扬，鸡苗价格高位偏强。 父母代产能方面，2025 年 10 月协会样本点在产父母代存栏 2307 万套，同比 +2.5%，环比+0.7%；后备父母代种鸡平均存栏量 1532 万套，同比-6.8%，环比 -2.2%。10 月父母代鸡苗价格为 47.79 元/套，最新报价 25 年第 44 周数据为 45.97 元/套。 综合来看，鸡苗端环比上涨，毛鸡养殖端环比下降。10 月毛鸡养殖亏损 1.78 元/羽，环比盈利大幅下降；孵化场盈利 0.65 元/羽，环比盈利大幅扩张。 行业研究 农林牧渔 2025 年 11 月 23 日 推荐（维持） 华创证券研究所 证券分析师：张皓月 邮箱：zhanghaoyue@hcyjs.com 执业编号：S0360524070009 证券分析师：陈鹏 电话：021-20572579 邮箱：chenpeng1@hcyjs.com 执业编号：S0360521080002 行业基本数据 | | | 占比% | | --- | --- | --- | | 股票家数(只) ...

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 82.5 CNY [2][10]. Core Insights - The company's main operations continue to improve, with significant progress in innovative drug development. The third quarter of 2025 saw a revenue of 365 million CNY, a slight decrease of 1.55%, while the net profit attributable to shareholders increased by 18.52% to 83.59 million CNY, and the non-GAAP net profit rose by 27.85% to 69.19 million CNY [2][4]. Financial Performance - Total revenue projections for the company are as follows: 1,350 million CNY for 2024, 1,376 million CNY for 2025, 1,683 million CNY for 2026, and 2,106 million CNY for 2027, with year-on-year growth rates of 20.8%, 2.0%, 22.3%, and 25.2% respectively [5][11]. - The net profit attributable to shareholders is projected to be 238 million CNY in 2024, 277 million CNY in 2025, 339 million CNY in 2026, and 423 million CNY in 2027, reflecting growth rates of 5.1%, 16.2%, 22.5%, and 24.7% respectively [5][11]. - Earnings per share (EPS) are expected to increase from 1.35 CNY in 2024 to 2.40 CNY in 2027 [5][11]. Strategic Developments - The company has strategically increased its stake in Shanghai Chaoyang Pharmaceutical to 51.48%, enhancing its innovative drug pipeline and R&D capabilities in cutting-edge technologies such as molecular glue and PROTAC [4]. - The core product HP-001 (molecular glue) has shown promising safety in phase I clinical trials, with symptom improvement observed in patients, indicating "Best-in-Class" potential [4]. - The company has also received IND approval for its ADC drug YLSHO03 and is set to initiate phase I clinical trials [4]. Market Position - The company is positioned to benefit from the rapid release of new products and the management of generic drug R&D investments, despite facing challenges from the tenth batch of national procurement [10]. - The internationalization of its formulations has seen breakthroughs, with the naloxone nasal spray production line passing FDA inspections and awaiting final reports [10].

Investment Rating - The report maintains a "Recommendation" rating for the insurance industry, expecting the industry index to outperform the benchmark index by over 5% in the next 3-6 months [21]. Core Insights - The insurance index fell by 3.06% this week, outperforming the broader market by 0.71 percentage points. Major insurance stocks experienced declines, with notable drops from Sunshine Insurance (-4.8%) and China Pacific Insurance (-4.57%) [1]. - The China Actuarial Society released the "Guidelines for Expense Allocation of Life Insurance Products," which aims to enhance the scientific management of expenses within insurance companies and supports the implementation of the "reporting and operation integration" policy [2][4]. - As of the end of 2024, 34 insurance asset management companies managed a total of CNY 33.30 trillion, reflecting a year-on-year growth of 10.60% [2]. - The report highlights that 172 insurance companies have disclosed their solvency data for Q3 2025, with 14 achieving an AAA risk rating, while 4 companies fell below solvency standards [2]. Summary by Sections Market Performance - The insurance sector's performance was characterized by a 3.06% decline in the insurance index, with individual stocks like China Life and Ping An also showing significant decreases [1]. Regulatory Developments - The newly released guidelines categorize life insurance business expenses into variable and fixed costs, specifying which expenses should not be allocated and providing methods for expense allocation [4]. Financial Data - The total market capitalization of the insurance sector is CNY 32,109.56 billion, with a circulating market value of CNY 22,103.29 billion [6]. Valuation Metrics - The report provides PEV valuations for major life insurance companies, with China Life at 0.83x and Ping An at 0.71x [5]. - For property insurance, the PB valuations are noted, with China Re at 0.58x and PICC at 1.2x [10]. Investment Recommendations - Short-term recommendations focus on companies with performance elasticity, suggesting investments in New China Life, China Property & Casualty, and China Life. Long-term recommendations include China Pacific Insurance and China Ping An based on fundamental and valuation considerations [10].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The fiscal policy in 2026 is expected to maintain an active tone to support stable growth, with a projected fiscal policy combination of a 4% deficit - rate (5.88 trillion yuan deficit), 2 trillion yuan in special treasury bonds, 4.7 trillion yuan in special local bonds, and 2 trillion yuan in replacement bonds, corresponding to 14.6 trillion yuan in net government bond financing [1][11][13]. - The government - sector leverage ratio is expected to rise to 74.6% in 2026, with a slightly slower upward slope compared to 2025 [1][15]. - The net financing of interest - rate bonds in 2026 is expected to be 17.1 trillion yuan, an increase of 0.8 trillion yuan compared to 2025, and the supply rhythm is in line with the front - loaded fiscal policy [2][16]. - After the "last dip" in the bond market, it is advisable to layout for the year - end pre - emptive market. The bond market strategy should flexibly switch between α and β strategies [4]. 3. Summary According to the Table of Contents 3.1 2026 Bond Supply Outlook - Fiscal Policy: The fiscal policy in 2026 is expected to remain active, but with limited room for further increasing the deficit rate. "Quasi - fiscal" tools may still have room for action [1][11]. - Government Bond Net Financing: The net government bond financing in 2026 is expected to be 14.6 trillion yuan, including 7.1 trillion yuan in treasury bonds, 7.5 trillion yuan in local bonds. The government - sector leverage ratio is expected to rise to 74.6%, with a slower growth rate, and the central and local government leverage ratios are expected to rise to 32.1% and 42.5% respectively [1][15][16]. - Interest - Rate Bond Net Financing: The net financing of interest - rate bonds in 2026 is expected to be 17.1 trillion yuan, including 7.1 trillion yuan in treasury bonds, 7.5 trillion yuan in local bonds, and 2.5 trillion yuan in policy - bank bonds. The supply rhythm is front - loaded, and the supply in the fourth quarter may be relatively small [2][16][19]. - Impact of Unused Quotas: If unused quotas are considered, there is still room for an increase in government bond supply in 2026, which may be decided based on economic conditions [3][20]. 3.2 Bond Market Strategy: Layout for the Year - End Pre - emptive Market after the "Last Dip" - Current Situation of 10 - year Treasury Bonds: The 10 - year treasury bonds are currently fluctuating narrowly around 1.8%, which is in the middle of the central bank's attention range. Due to limited expectations of interest - rate cuts this year and the unimplemented fund fee - rate regulations, the bond market lacks a trading theme, and 1.8% has become a short - term neutral psychological point formed by institutional games [4][28]. - Seasonal Pattern: Historically, there has often been a "last dip" in mid - to late November. After the negative factors are exhausted, the bond's allocation value becomes prominent, and institutions such as rural commercial banks usually start building positions, driving down yields [4]. - Strategy Switch: The α - mining strategy for medium - term bonds is nearing its end, and it is advisable to gradually switch back to the β strategy. There may be opportunities for both α and β in ultra - long - term bonds in December [34]. - Interest - Rate Bond Selection: Currently, bonds with α - space can be selected from multiple dimensions such as riding, variety spreads, and term spreads. A dumbbell strategy can be adopted to participate in short - term and ultra - long - term bonds [5][35]. 3.3 Interest - Rate Bond Market Review: The Bond Market Lacks a Trading Theme, and Yields Remain Narrowly Fluctuating - Overall Market: In the third week of November, the 10 - year treasury bond yields fluctuated weakly around 1.8%. The 1 - year treasury bond yield decreased by 0.5BP to 1.4%, the 10 - year treasury bond yield increased by 0.75BP to 1.8125%, and the 30 - year treasury bond yield increased by 1.05BP to 2.1585% [9]. - (1) Funding Situation: The central bank made large - scale net injections through open - market operations (OMO), and the funding situation was balanced but tight [10][52]. - (2) Primary Issuance: The net financing of policy - bank bonds increased, while the net financing of treasury bonds, local bonds, and inter - bank certificates of deposit decreased [52]. - (3) Benchmark Changes: The term spread of treasury bonds widened, while the term spread of China Development Bank bonds narrowed. The short - term treasury bonds performed better than the long - term ones, and the long - term China Development Bank bonds performed better than the short - term ones [50].

公司研究 证 券 研 究 报 告 卫信康（603676）2025 年三季报点评 推荐（下调） 非经事项扰动短期业绩，期待后续经营改善 目标价：15.4 元 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,300 | 1,222 | 1,414 | 1,659 | | 同比增速(%) | -1.7% | -6.0% | 15.8% | 17.3% | | 归母净利润(百万) | 246 | 273 | 336 | 413 | | 同比增速(%) | 15.0% | 10.7% | 23.4% | 22.9% | | 每股盈利(元) | 0.57 | 0.63 | 0.77 | 0.95 | | 市盈率(倍) | 19 | 17 | 14 | 12 | | 市净率(倍) | 3.4 | 3.0 | 2.6 | 2.2 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 11 月 21 日收盘价 化学制剂 2025 年 11 月 23 日 | | | 华创证券研究所 证券分析师：郑辰 ...

Investment Rating - The report maintains a "Recommendation" rating for Tonghua Dongbao, with a target price of 11.0 CNY per share [2][8]. Core Insights - The company reported a significant recovery in operating profit and steady progress in internationalization. In Q3 2025, the company achieved revenue of 806 million CNY, a year-on-year increase of 13.90%, and a net profit attributable to shareholders of 984 million CNY, a remarkable growth of 499.86%, primarily due to investment income from the transfer of equity in Te Bao Biotech [2][8]. - For the first three quarters of 2025, the company recorded total revenue of 2.18 billion CNY, up 50.55% year-on-year, with a net profit of 1.20 billion CNY and a non-recurring net profit of 321 million CNY [2][8]. Financial Performance Summary - The total revenue forecast for 2025 is 2.75 billion CNY, with a year-on-year growth rate of 37.0%. The net profit attributable to shareholders is projected to be 1.40 billion CNY, reflecting a staggering growth rate of 3,366.2% compared to the previous year [4][9]. - The earnings per share (EPS) for 2025 is estimated at 0.71 CNY, with a price-to-earnings (P/E) ratio of 12 times [4][9]. - The company’s total assets are expected to reach 8.54 billion CNY by 2025, with a debt-to-equity ratio of 13.2% [9]. Business Development Highlights - The company’s insulin analogs are experiencing rapid growth, with a projected 50% increase in sales year-on-year for Q3 2025, surpassing human insulin revenue [8][9]. - The company is advancing its international business, with the BLA for Aspart Insulin accepted by the FDA, and plans to continue with the BLA submissions for Glargine and Lispro [8][9]. - An employee stock ownership plan has been introduced, aiming to enhance the motivation of core employees, with a maximum of 11.08 million shares to be allocated [8][9].

- The report includes multiple quantitative models for market timing, categorized into short-term, mid-term, and long-term models, such as the "Volume Model," "Feature Volume Model," "Smart Algorithm Model," "Up-Down Return Difference Model," "Calendar Effect Model," and "Long-Term Momentum Model" [1][11][12][13][63][64] - The "Volume Model" is constructed based on trading volume data to predict market trends, while the "Feature Volume Model" incorporates specific volume characteristics to enhance prediction accuracy [11][63] - The "Smart Algorithm Model" uses machine learning techniques to analyze historical data and generate market timing signals [11][63] - The "Up-Down Return Difference Model" calculates the difference between upward and downward returns to assess market sentiment [12][63] - The "Calendar Effect Model" leverages historical seasonal patterns to predict market movements [12][63] - The "Long-Term Momentum Model" focuses on long-term price trends to identify potential upward movements [13][64] - The report evaluates the models as effective tools for market timing, emphasizing their simplicity and universality, aligning with the principle of "大道至简" (great simplicity) [8][63] - The models are tested across various indices, including the Shanghai Composite Index, CSI 300, and CSI 500, with signals ranging from neutral to bearish for short-term models and bullish for long-term models [11][63][64] - The "Volume Model" shows neutral signals across all broad-based indices [11][63] - The "Feature Volume Model" indicates bearish signals for the CSI 500 and All-A indices [11][63] - The "Smart Algorithm Model" provides neutral signals for the CSI 300 and bearish signals for the CSI 500 [11][63] - The "Up-Down Return Difference Model" transitions from bullish to neutral for the CSI 2000 and All-A indices [12][63] - The "Long-Term Momentum Model" maintains bullish signals for long-term market trends [13][64]

Investment Rating - The report maintains a "Strong Buy" rating for Shaanxi Coal and Chemical Industry Co., Ltd. (601225) [1] Core Views - The company's revenue for the first three quarters of 2025 was CNY 118.08 billion, a year-on-year decrease of 12.81%. The net profit attributable to shareholders was CNY 12.71 billion, down 27.22% year-on-year [1] - The report highlights that coal prices are on the rise, supporting profit recovery, and the coal-electricity integration strengthens long-term advantages [1] - The report anticipates that coal prices will continue to rise in the fourth quarter due to increased winter storage demand from downstream power plants and stricter safety inspections affecting coal production [7] Financial Performance Summary - For Q3 2025, the company achieved revenue of CNY 40.10 billion, a year-on-year decrease of 20.91%, but a quarter-on-quarter increase of 6.03%. The net profit attributable to shareholders was CNY 5.07 billion, down 26.59% year-on-year but up 79.08% quarter-on-quarter [1] - The average selling price of coal for the first three quarters of 2025 was CNY 540.2 per ton, a decrease of 12.63% year-on-year, while the production and sales volumes were 130.37 million tons and 189.20 million tons, respectively, showing slight year-on-year increases of 2.03% and 0.40% [7] - The report projects net profits for 2025-2027 at CNY 17.94 billion, CNY 20.59 billion, and CNY 23.35 billion, respectively, with corresponding PE ratios of 12x, 11x, and 10x [7] Market Position and Strategy - The company is enhancing its coal production capacity, with recent approvals for capacity increases at its coal mines, which will contribute to stable growth in its coal business [7] - The integration of coal and electricity production is expected to improve the company's profitability, creating a complete industrial chain from coal mining to electricity generation [7] - The current dividend yield is approximately 4.8%, based on a 60% payout ratio for 2025 [7]